Company news
SELLAS Life Sciences Group, Inc. news in 2024
SELLAS Life Sciences Group, Inc.'s news releases, calls and decks from 2024, newest first.
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
December 9, 2024
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
December 8, 2024
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
November 26, 2024
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
November 4, 2024
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia
October 14, 2024
SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
October 9, 2024
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
August 5, 2024
SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market
July 30, 2024
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
July 15, 2024
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
July 7, 2024
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
June 23, 2024
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
June 16, 2024
SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML
June 9, 2024
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
April 30, 2024
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study
April 28, 2024
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
March 27, 2024
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
March 25, 2024
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8: 15 am ET
March 18, 2024
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
March 14, 2024
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
March 7, 2024
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
February 29, 2024
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
February 28, 2024
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
February 5, 2024
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
January 24, 2024
SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients
January 8, 2024
SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering
January 3, 2024
SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
January 2, 2024
SELLAS Life Sciences Announces Proposed Public Offering
January 2, 2024
Decks in 2024
- Technical Presentation (November 2024)
Technical · 8 slides · November 2024